Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

Cancer Biology and Therapy

Volumn 8, Issue 21, 2009, Pages 2004-2009

  Yang, Sherry X ^a   Kummar, Shivaani ^a   Steinberg, Seth M ^a   Murgo, Anthony J ^a   Gutierrez, Martin ^a   Rubinstein, Larry ^a   Nguyen, Dat ^a   Kaur, Gurmeet ^a   Chen, Alice P ^a   Giranda, Vincent L ^b   Tomaszewski, Joseph E ^a   Doroshow, James H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

ABT 888; Immunohistochemistry; PARP; Phase 0 clinical trial; Solid tumors and lymphomas

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADENOCARCINOMA; ARTICLE; AUDITORY CANAL; CANCER RECURRENCE; CONCENTRATION (PARAMETERS); ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; NONHODGKIN LYMPHOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; TONGUE CARCINOMA; TUMOR BIOPSY;

EID: 73549089255     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.21.9917     Document Type: Article

References (28)

1. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-28.
2. Oliver FJ, Menissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis and disease. Am J Hum Genet 1999; 64:1282-8.
3. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004; 23:7322-9.
4. Rouleau M, Aubin RA, Poirier GG. Poly(ADP-ribosyl) ated chromatin domains: access granted. J Cell Sci 2004; 117:815-25.
5. Davidovic L, Vodenicharov M, Affar EB, Poirier GG. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 2001; 268:7-13.
6. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13:1383-8.
7. th International Symposium on Targeted Anticancer Therapies 2009; 7:68.
8. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
9. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14:7917-23.
10. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007; 13:3033-42.
11. Audeh MW, Penson RT, Friedlander M. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009; 27:277.
12. Tutt A, Robson M, Garber JE. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27:7.
13. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009; 27:2705-11.
14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45.
15. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100:207-12.
16. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22:3080-90.
17. Tan AR, Steinberg SM, Parr AL, Nguyen D, Yang SX. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann Oncol 2008; 19:185-90.
18. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8:1323-7.
19. Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25:3421-7.
20. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, et al. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res 2008; 14:6877-85.
21. Sedelnikova OA, Bonner WM. GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006; 5:2909-13.
22. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, et al. Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results. J Clin Oncol 2008; 26:3580.
23. Champe PCA. HR. Enzymes. Biochemistry 1994; 2:57-8.
24. Menegazzi M, Scarpa A, Carcereri de Prati A, Menestrina F, Suzuki H. Correlation of poly(ADPribose) polymerase and p53 expression levels in highgrade lymphomas. Mol Carcinog 1999; 25:256-61.
25. Ying W, Sevigny MB, Chen Y, Swanson RA. Poly(ADPribose) glycohydrolase mediates oxidative and excitotoxic neuronal death. Proc Natl Acad Sci USA 2001; 98:12227-32.
26. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004; 10:4813-21.
27. Yang SX, Simon RM, Tan AR, Nguyen D, Swain SM. Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 2005; 11:6226-32.
28. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-77.